Theratechnologies’ CEO and CFO to Attend Bloom Burton Healthcare Investor Conference in Toronto

MONTREAL, April 30, 2018 -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) is pleased to announce that Luc Tanguay, President and Chief Executive Officer will make a presentation at the 2018 Bloom Burton Healthcare Investor Conference on May 3, 2018.

“Our presentation will focus on our plan for future growth which, of course, includes Trogarzo™ (ibalizumab-uiyk) injection in the United States and Europe, EGRIFTA^® (tesamorelin for injection) in the United States and other territories as well as other potential initiatives aimed at creating value for our shareholders,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

“We look forward to meet current and potential investors to discuss our plan and to demonstrate how we intend to sustain the momentum we have been witnessing at Theratechnologies lately,” added Philippe Dubuc, Senior Vice President and Chief Financial Officer, Theratechnologies Inc.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.

Forward-Looking Information
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the growth of the Corporation based on Trogarzo™, EGRIFTA^® and potential initiatives.

Forward-looking statements are based on a number of assumptions including that the plan for future growth of the Corporation will materialize.

Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, among others, the risk that we may not find products that are compatible with our commercial platform, or that those products do not generate the anticipated revenues and cash flow, the risk that unexpected events slow the growth of Trogarzo^TM and/or a decrease in sales of EGRIFTA^®.

We refer potential investors to the "Risk Factors" section of our annual information form dated February 6, 2018 for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236